Combinatorial chemistry in cancer drug development.
The field of combinatorial chemistry has grown at an enormous rate in recent years, both in response to high-throughput capabilities and the discovery of a plethora of novel therapeutic targets. This review attempts to outlinethe recent developments of combinatorial chemistry in the search for novel cancer-related therapeutic agents.
Leonard
K A
KA
Department of Chemistry, Yale University, New Haven, Connecticut 06520, USA.
Deisseroth
A B
AB
Austin
D J
DJ
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use*; D001685:Biological Factors / Q000138:chemical synthesis; D020650:Combinatorial Chemistry Techniques / Q000379:methods*; D015195:Drug Design; D006801:Humans; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D017239:Paclitaxel / Q000138:chemical synthesis; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D001685:Biological Factors; D008565:Membrane Proteins; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases; D010749:Phosphoprotein Phosphatases; D017027:Protein Tyrosine Phosphatases; D017239:Paclitaxel